HALO vs VNDA: fair value comparison
Halozyme Therapeutics, Inc. and Vanda Pharmaceuticals Inc. · Updated 2026-09-12
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, HALO currently sits closer to the top of our discount ranking. HALO carries the stronger quality grade.
| HALO | VNDA | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $107.72 | $5.42 |
| 12-month range | $63.96–$107.72 | $4.47–$8.25 |
| Sector rank | #36 of 113 Healthcare | #41 of 113 Healthcare |
| Quality grade | A | D |
| Leverage | High | Low |
| Margin trend | Contracting | Stable |
| Revenue growth | High | Strong |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | Mixed |
| DCF cross-check | Undervalued | — |
| 52-week position | The top quarter | The lower-middle quarter |
Full single-stock breakdowns: HALO fair value analysis · VNDA fair value analysis